Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab with delayed pertuzumab use in HER2-positive breast cancer
ChiCTR2000032568Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab and pertuzumab in breast cancer (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Invasive disease-free survival. Started Apr 2020; status: recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000032568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032568.